Latest news and press releases about Eledon Pharmaceuticals, Inc. (ELDN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells.
Price
| Price | $2.67 |
| Market Cap | $206M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 4.21 |
| EV / EBITDA | -2.80 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -136.45% |
| Return on Invested Capital | -73.77% |
| Return on Assets | -78.16% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABEO · ACHV · ALLO · AVIR · EDIT · HUMA · PBYI
Explore sector: Healthcare · Biotechnology
More sections of ELDN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks